1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Abbvie Inc

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
Richard Gonzalez

1 N Waukegan Rd
North Chicago, Illinois 60064-1802
Phone: 18479327900


Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer
Apr 23, 2024 12:00pm

Source:Kwhen Finance
EU regulators approve Pfizer antibiotic Emblaveo
Apr 22, 2024 14:14pm

EU regulators have approved Pfizer (PFE) and AbbVie’s (ABBV) antibiotic product Emblaveo for the treatment of serious infections due to multi-drug resistant Gram-negative bacteria.

Source:Seeking Alpha
The Bad News Heading Into AbbVie''s First-Quarter Earnings Report
Apr 19, 2024 16:43pm

AbbVie stock has slumped 10% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Source:Investor''s Business Daily
AbbVie Q1 Earnings Preview: No Repeat Of Last Year''s Q1 Disappointment
Apr 18, 2024 17:46pm

AbbVie soon releases Q1 2024 earnings and faces losing patent protection for its best-selling drug, Humira. Read why I expect a positive Q1 2024 from ABBV.

Source:Seeking Alpha
AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition
Apr 18, 2024 13:30pm

No summary available.

Source:Seeking Alpha
AbbVie''s Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis
Apr 18, 2024 13:30pm

WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with a 26-week steroid taper regimen in adult…

Source:Finanz Nachrichten
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
Apr 18, 2024 11:00am

No summary available.

Source:Seeking Alpha
OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle
Apr 18, 2024 10:34am

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE''s runway extension into 2026, pa…

Source:Finanz Nachrichten
Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions
Apr 17, 2024 18:42pm

On Tuesday, the FDA issued a warning regarding the dangers associated with counterfeit versions of AbbVie Inc’s (NYSE: ABBV ) Botox used for cosmetic purposes. The alert follows reports of adverse reactions among individuals who received injections of fake Botox across several states, prompting investigations by the FDA and the Centers for Disease Control and Prevention (CDC). Related: Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings . Nineteen cases involving harmful reactions have been documented in nine states, including Colorado, Florida, Illinois, Kentucky, Nebraska, New Jersey, New York, Tennessee, and Washington. These reactions occurred after individuals received injections of counterfeit Botox from unlicensed practitioners or in non-healthcare settings … Full story available on

CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Apr 17, 2024 13:26pm

No summary available.

Source:Seeking Alpha